← Back to Search

Corticosteroid

ACTH treatment for West Syndrome (PREVENT-WS Trial)

N/A
Waitlist Available
Led By Sookyong Koh, MD, PhD
Research Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Infants with pre-hypsarhythmia (Type 3 EEG) between 2 months to 12 months of age.
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

PREVENT-WS Trial Summary

West syndrome (WS) is a specific type of epilepsy (or seizure disorder) that has three features: infantile spasms (type of seizure), loss of milestones, and a specific pattern on electroencephalogram (EEG or brain wave test) called hypsarhythmia. The purpose of this study is to detect pre-hypsarhythmia in infants at high-risk for WS and determine whether treatment with ACTH will prevent WS.

Eligible Conditions
  • West Syndrome

PREVENT-WS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PREVENT-WS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evidence for improvement in the EEG one month following initiation of the 2 week course of low-dose ACTH.

PREVENT-WS Trial Design

1Treatment groups
Experimental Treatment
Group I: ACTH treatmentExperimental Treatment1 Intervention
Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.

Find a Location

Who is running the clinical trial?

Ann & Robert H Lurie Children's Hospital of ChicagoLead Sponsor
253 Previous Clinical Trials
5,187,700 Total Patients Enrolled
Thrasher Research FundOTHER
132 Previous Clinical Trials
94,346 Total Patients Enrolled
Sookyong Koh, MD, PhDPrincipal InvestigatorAnn & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Controlled Clinical TrialsJournal
Optimal Two-stage Designs for Phase II Clinical Trials
Simon, Richard. 1989. “Optimal Two-stage Designs for Phase II Clinical Trials”. Controlled Clinical Trials. Elsevier BV. doi:10.1016/0197-2456(89)90015-9.
clinicaltrials.govStudy
Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)
John J Millichap, MD 2011. "Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01367964.
All > Acth
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top